I can't see why it is disappointing. Cohort A are people who are not getting any great benefit from Keytruda so it is game over for them. Efti improves their chances by a third. And cohort B start out as high risk patients(probably deemed not to have a great chance on Keytruda alone (although I don't know the details), they get a 50% response rate. And it is safe. This looks good for the next phase of the trial.
I can't see why it is disappointing. Cohort A are people who are...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.025(8.77%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 31.0¢ | 29.0¢ | $960.3K | 3.208M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1353 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 36123 | 3 |
View Market Depth
| Last trade - 15.59pm 22/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
